Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ursodeoxycholic acid + silymarin** is a fixed-dose combination of two distinct hepatoprotective agents used for the management of liver diseases. Ursodeoxycholic acid, a hydrophilic bile acid, acts primarily by replacing cytotoxic bile acids, improving bile flow, and reducing cholesterol saturation, thereby aiding in the management of cholestatic liver disorders and certain gallstone conditions[2][5][8]. Silymarin, an extract from *Silybum marianum* (milk thistle), is a potent antioxidant and free radical scavenger that protects hepatocytes from oxidative stress and membrane injury, modulates inflammation, and inhibits fibrogenesis, thus supporting hepatic repair[3][6][9]. The combination is used in various acute and chronic liver disorders, including viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and primary biliary cholangitis[1][7][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ursodeoxycholic acid + silymarin.